 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...110111112113114115116117118119120...235236» |
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
SUSCEPTIBILITY TO IMMUNE ELIMINATION OF EPITHELIAL AND QUASI-MESENCHYMAL PANCREATIC DUCTAL ADENOCARCINOMA CELLS UNDER BASAL CONDITIONS AND FOLLOWING TREATMENT WITH FOLFIRINOX ([VIRTUAL]) - Dec 17, 2021 - Abstract #APCM2021APCM_63;
FOLFIRINOX induced increased susceptibility of PDAC cells to immune elimination irrespective of subtype and target TA expression.
- irinotecan / Generic mfg.
TARGETING DNA REPAIR PROTEIN, BARD1, IN PANCREATIC DUCTAL ADENOCARCINOMA ([VIRTUAL]) - Dec 17, 2021 - Abstract #APCM2021APCM_14;
In this study, we found that targeting BARD1 provides an exciting therapeutic opportunity with the potential to greatly benefit PDAC patient outcomes. Future studies are aimed to explore the effects of targeting BARD1 in a relevant mouse model of PDAC.
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
GOAL-DIRECTED NEOADJUVANT TREATMENT OF OPERABLE PANCREATIC CANCER: ACHIEVING CA19-9 RESPONSE TO CHEMOTHERAPY PRIOR TO SURGERY ([VIRTUAL]) - Dec 17, 2021 - Abstract #APCM2021APCM_9;
Once patients achieve normalization of CA19-9 with chemotherapy, it may be reasonable to progress to the next treatment modality. However, treatments cannot be continued indefinitely, and achieving a ≥50% decline in CA19-9 with neoadjuvant chemotherapy may be a clinically important threshold.
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
#TumorBoardTuesday walking through metastatic GEA- from handling onc 🚨 to planning out tx through 3L. 🤔DYK PD-1 tx upfront (FOLFOX + nivo) can ⬆️RR to ram +tax in 2L? Thanks to @doctorC369 for guiding us through an excellent discussion & always thinking 3 steps ahead! (Twitter) - Dec 17, 2021
- |||| Clinical: thanks! this particular GEJ adenoCA patient became neutropenic after 2 cycles of FOLFOX&nivolumab, so added pegfilgrastim after cycles 3&4. but because of an immune-mediated aortitis after cycle 4, stopped both nivo and pegfilgrastim. hope stopping bolus can help keep ANC up 🤞🏻 (Twitter) - Dec 17, 2021
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: should the bolus be avoided in all lines of FOLFOX therapy, across all indications? like first-line in metastatic esophageal adenoCA, as one specific example (Twitter) - Dec 17, 2021
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. (Pubmed Central) - Dec 16, 2021
However, treatments cannot be continued indefinitely, and achieving a ≥50% decline in CA19-9 with neoadjuvant chemotherapy may be a clinically important threshold. The basal-like subtype is chemoresistant and can be distinguished from classical PDAC by GATA6 expression.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal: Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and is Measurable with Collagen-Targeted Molecular MRI. (Pubmed Central) - Dec 16, 2021
In humans, post-chemoradiation tumor fibrosis is associated with OS and DFS. In mice, our MR findings indicate that translation of collagen molecular MRI with CM-101 to humans might provide a novel imaging technique to monitor fibrotic response to therapy in order to assist with prognostication and disease management.
- || Avastin (bevacizumab) / Roche
Clinical, Journal, Real-world evidence: Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice. (Pubmed Central) - Dec 16, 2021
In mice, our MR findings indicate that translation of collagen molecular MRI with CM-101 to humans might provide a novel imaging technique to monitor fibrotic response to therapy in order to assist with prognostication and disease management. The addition of bevacizumab to a first-line chemotherapeutic regimen provides survival benefits in a real-world setting for mCRC patients who cannot undergo curative-intent local treatment for metastatic lesions.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., probenecid / Generic mfg.
Review, Journal: Desirable drug-drug interactions or when a matter of concern becomes a renewed therapeutic strategy. (Pubmed Central) - Dec 16, 2021
More recently, some drug-drug combinations have been integrated in modern drug design strategies, aiming to enhance the efficiency of already marketed drugs with new compounds acting not only as synergistic associations, but also as real boosters of activity. In this review, we provide an update of examples of such strategies, with a special focus on microbiology and oncology.
- || Clinical, Journal: Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey. (Pubmed Central) - Dec 16, 2021
In this review, we provide an update of examples of such strategies, with a special focus on microbiology and oncology. The IDEA results have been practice-changing as French physicians have implemented 3 months of CAPOX for patients with low-risk stage III CC, substituting from 6 months of FOLFOX, which remains the preferred regimen for high-risk patients.
- || irinotecan / Generic mfg.
Clinical, Journal: Occurrence and Management of Thrombocytopenia in Metastatic Colorectal Cancer Patients Receiving Chemotherapy: Secondary Analysis of Data From Prospective Clinical Trials. (Pubmed Central) - Dec 16, 2021
CIT was common among mCRC patients receiving the FOLFOX4 regimen. The most frequent consequence of CIT was a delay in chemotherapy, highlighting the unmet need in CIT management.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. (Pubmed Central) - Dec 16, 2021
FOLFIRINOX for LAPA and BRPA seems to be effective with a manageable toxicity profile. These promising results in "real-life" patients now have to be confirmed in a Phase 3 randomised trial.
- || oxaliplatin / Generic mfg.
Clinical, Journal: Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients. (Pubmed Central) - Dec 16, 2021
IDEA risk classification per se does not predict benefit from addition of oxaliplatin to adjuvant chemotherapy in stage III colon cancer. T4 disease may predict lack of benefit from oxaliplatin addition.
- | leucovorin calcium / Generic mfg.
Journal: Formate test for bedside diagnosis of methanol poisoning. (Pubmed Central) - Dec 16, 2021
The diagnosis was some hours later confirmed by GC-MS, showing a methanol concentration of 62 mmol/L (200 mg/dL) and a formate concentration of 19 mmol/L. Implementation of this technology into routine clinical use can potentially offer an opportunity for a step-change in the management of methanol poisoning.
- || irinotecan / Generic mfg.
Clinical, Journal: Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II). (Pubmed Central) - Dec 16, 2021
This trial protocol describes the PelvEx II study. PelvEx II, designed as a multicentre, open-label, phase III, parallel-arms study, is the first randomized study to compare induction chemotherapy followed by neoadjuvant chemo(re)irradiation and surgery with neoadjuvant chemo(re)irradiation and surgery alone in patients with locally recurrent rectal cancer, with the aim of improving the number of R0 resections.
- || Avastin (bevacizumab) / Roche
Clinical, Journal: Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. (Pubmed Central) - Dec 16, 2021
Gene expression analysis failed to identify patients with BRAF-mutant mCRC candidate to upfront FOLFOXIRI/bevacizumab. ECOG-PS >0 and left-sidedness seem associated with no benefit from the intensified treatment.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Retrospective data, Review, Journal: ASO Visual Abstract: Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer-A Systematic Review and Meta-analysis. (Pubmed Central) - Dec 16, 2021
ECOG-PS >0 and left-sidedness seem associated with no benefit from the intensified treatment. No abstract available
- || Avastin (bevacizumab) / Roche
Clinical, Journal, HEOR: Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia. (Pubmed Central) - Dec 16, 2021
No abstract available Using either a healthcare or societal perspective, the addition of bevacizumab for mCRC treatment was considered not cost-effective.
- || methotrexate IV / Generic mfg., leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Clinical, Journal: Reduced dose folinic acid rescue after rapid high-dose methotrexate clearance is not associated with increased toxicity in a pediatric cohort. (Pubmed Central) - Dec 16, 2021
Using either a healthcare or societal perspective, the addition of bevacizumab for mCRC treatment was considered not cost-effective. A pharmacokinetically guided FA rescue of one or two 15 mg/m doses of FA following HD-MTX courses with rapid MTX clearance results in a shorter hospitalization without an increase in toxic effects.
- || irinotecan / Generic mfg.
Clinical, P2 data, Journal: Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. (Pubmed Central) - Dec 16, 2021
Maintenance with leucovorin plus fluorouracil appears to be feasible and effective in patients with mPC controlled after 4 months of induction chemotherapy with FOLFIRINOX. Severe neurotoxicity was higher in the maintenance therapy arm, probably because of the higher cumulative dose of oxaliplatin.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal, BRCA Biomarker, PARP Biomarker: Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy. (Pubmed Central) - Dec 16, 2021
Patients with APC who have higher carbohydrate antigen 19.9 and low albumin are less likely to have DC12. DC12 is significantly associated with longer PFS and OS.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Journal, HEOR: Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer. (Pubmed Central) - Dec 16, 2021
Differences in costs between the two arms (encorafenib plus cetuximab vs FOLFIRI plus cetuximab) was 59 501 €, with a cost of 17 500 € per month of overall survival-gain. Combining pharmacological costs of drugs with the measure of efficacy represented by overall survival, at the actual prize encorafenib cannot be considered cost-effectiveness for second-line treatment of BRAFV600-mutated metastatic colorectal cancer.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Biomarker, Clinical, Journal: Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study. (Pubmed Central) - Dec 16, 2021
MiR-373-3p and miR-194-5p did not show an association with OS after adjustment for disease stage, baseline CA19-9, and chemotherapy response. In conclusion, high serum miR-373-3p before the start and low serum miR-194-5p after one cycle are associated with early tumor progression during FOLFIRINOX.
- | methotrexate / Generic mfg.
Retrospective data, Journal: Methotrexate Toxicity from Unintentional Dosing Errors: Calls to a Poison Center and Death Descriptions. (Pubmed Central) - Dec 16, 2021
Most methotrexate calls to our poison center resulted from taking the drug more often than prescribed. Efforts may focus on patient education, physician or pharmacist monitoring during initiation, improved dispensing devices, or weekly drug dispensing.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Pancreatic cancer (Pubmed Central) - Dec 16, 2021
Neoadjuvant chemotherapy regimens, such as FOLFIRINOX, represent a valid option in order to achieve complete surgical tumor resection in more advanced cases. However, the overall uptake of this promising concept is very low.
- |||| Clinical: 8/ #TumorBoardTuesday Back to the patient After 6 months progression, but ECOG PS 1 and symptomatically doing well👌🏽 🥐LFT- normal What will you do? 1. Ramucirumab +paclitaxel 2. FOLFIRI+ cetuximab 3. FOLFIRI + ramucirumab 4. Clinical trial (Twitter) - Dec 15, 2021
- || Zaltrap (ziv-aflibercept IV) / Sanofi
Trial primary completion date: mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer (clinicaltrials.gov) - Dec 15, 2021
P2, N=119, Active, not recruiting, Sponsor: AIO-Studien-gGmbH
However, the overall uptake of this promising concept is very low. Trial primary completion date: Aug 2021 --> Jan 2021
- | Avastin (bevacizumab) / Roche
Enrollment open, Combination therapy, Metastases: Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 15, 2021
P1, N=15, Recruiting, Sponsor: Ning Jin
Trial primary completion date: Aug 2021 --> Jan 2021 Not yet recruiting --> Recruiting
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Herceptin (trastuzumab) / Roche
Clinical: #TumorBoardTuesday The FOLFIRINOX regimen with or without trastuzumab was associated with improved ORR and PFS in patients with advanced gastroesophageal adenocarcinoma in the first-line setting. #PrecisionMedicine https://t.co/sJ3MYjA9NB (Twitter) - Dec 14, 2021
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Clinical, Journal, HEOR: The Appropriate First-Line Chemotherapy Regimen for Incurable Pancreatic Cancer in Clinical Practice: A Consideration of Patients' Overall Survival and Quality of Life. (Pubmed Central) - Dec 14, 2021
Japanese clinical practice guidelines further recommend GEM and tegafur/gimeracil/oteracil potassium (S-1)...In addition, a good HFS was obtained with S-1 alone in some cases. In the future, clinical trials for chemotherapy should examine QOL during the entire clinical course.
- || Cotellic (cobimetinib) / Exelixis, Roche
Clinical, Journal: Cobimetinib Plus Gemcitabine: An Active Combination in KRAS G12R-Mutated Pancreatic Ductal Adenocarcinoma Patients in Previously Treated and Failed Multiple Chemotherapies. (Pubmed Central) - Dec 14, 2021
Our pancreatic cancer patients were heavily pretreated (all had received FOLFIRINOX and gemcitabine/nab-paclitaxel) before the entry into our trial...This study illustrates a new discovery, which can potentially target 15-20% of pancreatic cancer patients and allow for a significant improvement in their prognosis. We will be conducting randomized phase II trials to substantiate our findings.
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
9/ #TumorBoardTuesday Case outcome ✅ Started: Ram🐏+tax 🗓Plan: FOLFIRI/Iri + cet @ 3rd L ✅ Will recheck EGFR by 💧 liquid bx 🔬(PMID: 33199443) @LizzySmyth1 (Twitter) - Dec 14, 2021
- ||| MK-1084 / Merck (MSD)
Enrollment open, Monotherapy: A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (clinicaltrials.gov) - Dec 14, 2021
P1, N=185, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
We will be conducting randomized phase II trials to substantiate our findings. Not yet recruiting --> Recruiting
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Pathologic Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy (Poster Board Number: 107; LACC West Exhibit Hall A) - Dec 13, 2021 - Abstract #USCAP2022USCAP_1444;
There is no significant difference in either DFS or OS between CAP grade 2 and 3. The ypT and ypN are also important prognostic factors in this group of treated PDAC patients.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinicopathologic Features of Adenocarcinoma Arising in Low-Grade Appendiceal Mucinous Neoplasm (Poster Board Number: 96; LACC West Exhibit Hall A) - Dec 13, 2021 - Abstract #USCAP2022USCAP_627;
Adenocarcinoma arising in LAMN is a rare entity with unique clinicopathologic features and important implications for clinical treatment. Further studies are needed to characterize its histologic features, molecular genetic profile, and clinical behavior in comparison to conventional LAMN.
- | Enrollment closed, Trial primary completion date: Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I (clinicaltrials.gov) - Dec 13, 2021
P1/2, N=50, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Further studies are needed to characterize its histologic features, molecular genetic profile, and clinical behavior in comparison to conventional LAMN. Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2022 --> Apr 2022
- leucovorin calcium / Generic mfg.
Hemiparesis in a Patient with FOLR1-Related Cerebral Folate Deficiency () - Dec 12, 2021 - Abstract #AES2021AES_641;
Early initiation of treatment with folinic acid is of paramount importance in CFD... Patient 1’s presentation may expand the clinical spectrum of FOLR1-related CFD to include stroke-like episodes.
- | Enrollment open: Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer (clinicaltrials.gov) - Dec 10, 2021
P1/2, N=120, Recruiting, Sponsor: Thomas Jefferson University
Patient 1’s presentation may expand the clinical spectrum of FOLR1-related CFD to include stroke-like episodes. Not yet recruiting --> Recruiting
- leucovorin calcium / Generic mfg.
Standardizing education and competency for oncology nurses reduces errors with high-dose methotrexate administration. (Anaheim Convention Center - Room 157/159) - Dec 9, 2021 - Abstract #ONS2022ONS_120;
The errors centered on, improper parameter management prior to administration of drug, incorrect timing of serum methotrexate levels, and delayed or missing RN interventions related to dosing and administration of leucovorin for cell rescue...A comprehensive education program and standardized approach is effective in reducing nursing errors and improving outcomes for patients receiving HDMTX. Insight from multiple disciplines is key to identifying barriers and providing best practices to reduce errors and improve outcomes for patients.
- | Bavencio (avelumab) / EMD Serono
Trial termination, Combination therapy, Metastases: Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 (clinicaltrials.gov) - Dec 9, 2021
P2, N=30, Terminated, Sponsor: National Cancer Institute (NCI)
Insight from multiple disciplines is key to identifying barriers and providing best practices to reduce errors and improve outcomes for patients. Completed --> Terminated; Terminated after an unplanned interim efficacy analysis.
- |||| Enweida (envafolimab) / 3DMed, Ascletis, suvemcitug (APX003) / Mabwell (Shanghai) Biosci, Pyxis Oncology
New P2 trial, Combination therapy, Metastases: A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 7, 2021
P2, N=110, Not yet recruiting, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
No mets to liver, just physical adherence of tumor Perforation & abscess formation at tumor site. The entire area resected en-bloc. Pt has MS, but is not getting any tx for it. Good performance status otherwise. Pt told to have 6m FOLFOX @TGeorgeMD @GIcancerDoc @VanMorrisMD (Twitter) - Dec 7, 2021
- | cisplatin / Generic mfg.
Retrospective data, Journal: First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis. (Pubmed Central) - Dec 6, 2021
The ABC-02 trial established the current first line (1L) standard systemic chemotherapy (CT) with gemcitabine/platinum derivate for advanced cholangiocarcinoma...However, individualized modifications of the therapy regimen allowed better tolerance as well as continuation of therapy and did not significantly influence median OS. Furthermore, our study revealed a potential survival benefit with 2L CT for selected patients.
- | uproleselan sodium (APL-106) / GlycoMimetics
New P1 trial, Combination therapy: NCI-2021-10020: Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane (clinicaltrials.gov) - Dec 6, 2021
P1, N=51, Not yet recruiting, Sponsor: Children's Oncology Group
- ||| lunresertib (RP-6306) / Repare Therap
New P1 trial, Combination therapy, Metastases: MINOTAUR: Study of RP-6306 With FOLFIRI in Advanced Solid Tumors (clinicaltrials.gov) - Dec 6, 2021
P1, N=104, Not yet recruiting, Sponsor: Repare Therapeutics
- | Trial completion, Trial completion date, Metastases: PRODIGE 37-FIRGEMAX: FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine (clinicaltrials.gov) - Dec 6, 2021
P2, N=127, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
Furthermore, our study revealed a potential survival benefit with 2L CT for selected patients. Active, not recruiting --> Completed | Trial completion date: Jul 2020 --> Mar 2021
- | Trial completion, Trial completion date, Metastases: PRODIGE 35-PANOPTIMOX: First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem (clinicaltrials.gov) - Dec 6, 2021
P2, N=276, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
Active, not recruiting --> Completed | Trial completion date: Jul 2020 --> Mar 2021 Active, not recruiting --> Completed | Trial completion date: Jul 2020 --> Aug 2021
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma. (Pubmed Central) - Dec 5, 2021
The incidence of grade 3/4 adverse events was not statistically different between the two groups (37.7% vs 28.1%; P = 0.242). D-TACE-HAIC was tolerable and led to better OS than DEB-TACE in patients with large or huge HCC, especially in those with non-smooth tumor margin or macrovascular invasion.
- oxaliplatin / Generic mfg.
Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials. (Available On Demand) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_656;
By contrast, EOD was not significantly associated with poorer outcomes. In case of relevant neurotoxicity during a 6 months schedule, these data are not in favor of continuing oxaliplatin beyond 75% of planned cycles of adjuvant chemotherapy, and demonstrate that fluoropyrimidines remain the cornerstone of adjuvant chemotherapy in localized CC.